Yousem Samuel A, Nikiforova Marina, Nikiforov Yuri
Department of Pathology, Presbyterian Campus, UPMC Presbyterian Shadyside, Pittsburgh, PA 15213, USA.
Am J Surg Pathol. 2008 Sep;32(9):1317-21. doi: 10.1097/PAS.0b013e31816597ca.
BRAF mutations in lung adenocarcinoma are much less common than the more frequently reported and mutually exclusive mutations of KRAS and EGFR genes, and the clinical and histologic phenotype of BRAF adenocarcinomas has not been described. We analyzed 222 adenocarcinomas of lung lacking KRAS and EGFR mutations and identified 10 adenocarcinomas with BRAF-V600E mutation. All BRAF-V600E mutations were heterozygous. There was a slight female predilection (6:4) in these elderly patients (average age 67 y) who were found to have a greater than expected incidence of intralobar satellite nodules and N2 node involvement. The adenocarcinomas were largely of mixed type with a high incidence of papillary (80%) and lepidic growth (50%). Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
与更常见且相互排斥的KRAS和EGFR基因突变更为常见,肺腺癌中的BRAF突变则要少见得多,并且BRAF腺癌的临床和组织学表型尚未得到描述。我们分析了222例缺乏KRAS和EGFR突变的肺腺癌,鉴定出10例具有BRAF-V600E突变的腺癌。所有BRAF-V600E突变均为杂合子。在这些老年患者(平均年龄67岁)中,女性略占优势(6:4),发现叶内卫星结节和N2淋巴结受累的发生率高于预期。腺癌大多为混合型,乳头状(80%)和鳞屑样生长(50%)的发生率较高。随着更多以基因为导向的药物疗法出现,具有这种临床病理表型的腺癌可能值得研究BRAF-V600E突变。